A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma

Published:2014-10 Issue:12 Volume:10 Page:1941-1951
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Wang Hong-kai¹²,Zhang Hai-liang¹²,Zhu Yao¹²,Yao Xu-dong¹²,Zhang Shi-lin¹²,Dai Bo¹²,Shen Yi-jun¹²,Zhu Yi-ping¹²,Shi Guo-hai²,Qin Xiao-jian¹²,Ma Chun-guang¹²,Lin Guo-wen¹²,Xiao Wen-jun¹²,Ye Ding-wei¹²

Affiliation:

1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China

2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

Abstract

ABSTRACT Aim: To investigate the role of sorafenib dosage escalation in Asian patients with metastatic renal cell carcinoma that had progressed after routine dosages. Patients & methods: Sorafenib dosage escalation to 600 or 800 mg twice a day was offered to 41 patients with metastatic renal cell carcinoma who had progressed on normal dosages. Clinical outcome, toxicity and favorable clinical covariables for progression-free survival (PFS) were evaluated. Results: The median PFS with dosage-escalated therapy was 7 months. Drug-related adverse events were tolerable. The pre-escalation Karnofsky performance status, serum calcium concentration, neutrophil/lymphocyte ratio, PFS and the highest toxicity grade at the routine dosage were associated with a longer PFS in the dosage-escalation period. Conclusion: Sorafenib dosage escalation was efficacious and tolerable in Asian patients. Trial registration: Chinese Clinical Trial Registry (no. ChiCTR-ONRC-12002088).

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.14.131

Reference28 articles.

1. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

3. Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

4. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuances to precision dosing strategies of targeted cancer medicines;Pharmacology Research & Perspectives;2020-07-13

2. A new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy;Translational Andrology and Urology;2019-08

3. Molecular-targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: A proposed strategy;International Journal of Urology;2018-10-01

4. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis;Clinical Genitourinary Cancer;2018-06

5. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis;Cancer Immunology, Immunotherapy;2018-02-08